BioCryst Pharmaceuticals
BCRX
BCRX
292 hedge funds and large institutions have $1.77B invested in BioCryst Pharmaceuticals in 2025 Q2 according to their latest regulatory filings, with 52 funds opening new positions, 112 increasing their positions, 84 reducing their positions, and 30 closing their positions.
New
Increased
Maintained
Reduced
Closed
more call options, than puts
Call options by funds: $ | Put options by funds: $
more first-time investments, than exits
New positions opened: | Existing positions closed:
more capital invested
Capital invested by funds: $ → $
more repeat investments, than reductions
Existing positions increased: | Existing positions reduced:
10.82% more ownership
Funds ownership: 83.4% → 94.22% (+11%)
7% more funds holding
Funds holding: 272 → 292 (+20)
67% less funds holding in top 10
Funds holding in top 10: 3 → 1 (-2)
Holders
292
Holding in Top 10
1
Calls
$12.7M
Puts
$6.52M
Top Buyers
| 1 | +$36.6M | |
| 2 | +$32.3M | |
| 3 | +$28.8M | |
| 4 |
Morgan Stanley
New York
|
+$27.2M |
| 5 |
D.E. Shaw & Co
New York
|
+$25.1M |
Top Sellers
| 1 | -$37.6M | |
| 2 | -$22.1M | |
| 3 | -$17.1M | |
| 4 |
Ameriprise
Minneapolis,
Minnesota
|
-$14.7M |
| 5 |
Alkeon Capital Management
New York
|
-$13.4M |
